Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and Contingent Value Right deal valued at up to $3.8b, putting fresh attention on the stock and its mental health pipeline.

AtaiBeckley’s merger announcement comes after a sharp move in the share price, with a 30-day share price return of 74.88% and year-to-date share price return of 85.27%. The 3-year total shareholder return of 251.47% highlights how sentiment around its mental health pipeline has shifted over time compared with the weaker 5-year total shareholder return.

If this Eli Lilly deal has you looking across the sector, it could be a useful moment to scan other mental health and biotech opportunities through our healthcare focused 39 healthcare AI stocks.

So is AtaiBeckley’s surge and takeover price mainly a vote of confidence in its mental health pipeline, or does it say more about changing sentiment as a large buyer steps in? And how does that stack up against fundamentals?

Preferred Price-to-Book Multiple of 13.4x: Is It Justified?

The Eli Lilly offer has shone a light on how the market is valuing AtaiBeckley today, and the preferred yardstick here is the P/B ratio. The stock is trading on a price-to-book multiple of 13.4x, alongside a last close of $7.17 and a market value of about $2.7b.

The P/B ratio compares the company’s equity value on the market to the net assets on its balance sheet. For a clinical stage biopharma such as AtaiBeckley, that usually means investors are paying primarily for the future potential of its mental health pipeline rather than existing earnings, because the company is currently loss making and does not yet have meaningful revenue at $3.5m.

What stands out is how rich that 13.4x looks next to the broader US pharmaceuticals industry, which sits around 2.5x. In other words, the stock is priced at more than 5x the sector average on this measure, even though AtaiBeckley is unprofitable, has a return on equity of a 333.78% loss, and is forecast to remain unprofitable over the next three years. At the same time, compared with its direct peer set where the average P/B is 23.1x, the valuation looks lower, which suggests investors in this specific niche of the sector may be assigning even higher balance sheet multiples to similar companies.

These contrasting comparisons leave you weighing a premium to the wider industry against a discount to peers that share a similar high risk, high research spend profile. With insufficient data for a fair P/B ratio model and no DCF estimate available, the P/B discussion becomes one of how much future pipeline potential you think is already reflected in that 13.4x multiple, particularly in light of recent share price volatility and past shareholder dilution.

Result: Price-to-Book of 13.4x (OVERVALUED)

However, AtaiBeckley’s story still hinges on clinical and regulatory milestones, and any setback around trials, approvals, or deal completion could quickly challenge the current takeover narrative.

Next Steps

If this mix of enthusiasm and caution around AtaiBeckley leaves you undecided, take a closer look at the numbers and move quickly to shape your own view by reviewing the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond AtaiBeckley?

If AtaiBeckley has sharpened your interest in what is possible with focused research, do not stop here. Broaden your watchlist with other targeted opportunities.

• Scan for resilience by checking companies with strong finances and consistent balance sheets through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for mispriced opportunities by reviewing the 38 high quality undervalued stocks that combine quality fundamentals with potentially attractive entry points.
• Spot early-stage potential by assessing the 21 elite penny stocks with strong financials that pair lower share prices with stronger financial profiles than many investors might expect.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.